CONGRESS GUIDE

Recommendations

Info

ERS International Congress 2016 INDUSTRY SPONSORED SESSIONS SUNDAY 04 SEPTEMBER, 2016 18:10 18:30 18:55 Making connections: a combination of factors Alberto Papi (FERRARA, Italy) Navigating the tube: inhaler characteristics in asthma Omar Usmani (London, United Kingdom) Reaching our destination: discussion David Price (Singapore, Singapore), Johann Christian Virchow (Rostock, Germany), Alberto Papi (FERRARA, Italy), Omar Usmani (London, United Kingdom) 1666 1667 1668 19:10 Journey’s end? David Price (Singapore, Singapore), Johann Christian Virchow (Rostock, Germany) Room G Session 277 17:15 - 19:15 Industry evening symposium: Device Matters | Looking beyond the drug Organised by Teva Branded Pharmaceutical Products R&D, Inc Chairs : Helen Reddel (Camperdown, NSW, Australia) 17:15 Welcome and introduction Helen Reddel (Camperdown, NSW, Australia) 1669 1670 17:20 17:40 18:00 18:20 18:40 Looking beyond the drug in asthma and COPD Kai Michael Beeh (Wiesbaden, Germany) Do inhalers and their correct use contribue to good patient management? John Haughney (Aberdeen, United Kingdom) Inhaler device mastery: results from handling studies Sinthia Bosnic-Anticevich (Sydney, Australia) The patient's perspective: what's happening outside the clinic? Henry Chrystyn (Bingley, United Kingdom) Bridging the gaps between guidelines and clinical care Helen Reddel (Camperdown, NSW, Australia) 1671 1672 1673 1674 1675 19:00 Summary and close Helen Reddel (Camperdown, NSW, Australia) Room D Session 278 17:15 - 19:15 Industry evening symposium: Therapies and Strategies – Stay Ahead in PAH Organised by Actelion Pharmaceuticals Ltd Chairs : Paul A. Corris (Newcastle, United Kingdom), Gérald Simonneau (Le Kremlin-Bicêtre, France) 17:15 Introduction Gérald Simonneau (Le Kremlin-Bicêtre, France) 1676 1677 17:25 17:45 18:05 18:25 18:45 Assessing risk in PAH – Why it is so important Sean Gaine (Dublin, Ireland) Dual oral combination – Why it is so relevant Ioana R Preston (Boston, United States of America) Triple oral combination – Who can benefit Olivier Sitbon (Le Kremlin-Bicêtre, France) i.v. therapy and transplantation – When to start Marius M. Hoeper (Hannover, Germany) From theory to practice – Interactive patient cases Paul A. Corris (Newcastle, United Kingdom) 1678 1679 1680 1681 1682 19:05 Panel discussion 1683 5 26.08.2016
ERS International Congress 2016 Room M Session 279 17:15 - 19:15 Industry evening symposium: NTM lung infections: challenging the current treatment approach Organised by Insmed Chairs : Michael Loebinger (London, United Kingdom) 17:15 NTM Overview Michael Loebinger (London, United Kingdom) INDUSTRY SPONSORED SESSIONS SUNDAY 04 SEPTEMBER, 2016 1684 17:55 18:25 Recent Developments in the Treatment of NTM Lung Infections Charles Daley (Denver, CO, United States of America) Hide and Seek: Drugs and Bugs in the Macrophage Jakko van Ingen (Nijmegen, Netherlands) 1686 1685 18:45 Question-and-answer Room P Session 280 17:15 - 19:15 Industry evening symposium: New Frontiers and Clinical Advances in Immunotherapy for Asthma:Focus on Biologics-Based Management of Moderate-to-Severe Asthma in Patients Failing ICS and LABA Organised by Sanofi and Regeneron Pharmaceuticals Chairs : Sally Wenzel (Pittsburgh, United States of America), Michael Wechsler (Denver, United States of America) 17:15 Welcome: Addressing New Challenges in Asthma Management Sally Wenzel (Pittsburgh, United States of America) 1687 17:20 17:40 18:00 18:20 18:45 Overview of Asthma Disease Burden, Epidemiology, and Spectrum of Allergic-Atopic Disorders: Where Have We Succeeded? Where is There Room for Improvement? How Well Are Our Patients with Asthma Really Doing? Christopher E. Brightling (Leicester, United Kingdom) The Unmet Need for New Therapies to Address Moderate-to-Severe Asthma in Patients Failing Inhaled Corticosteroids (ICS) and Long-Acting Beta-Agonists (LABA): Where and Why Are Current Therapies Failing? The Rationale for Novel Targets to Improve Clinical Outcomes in Asthma Michael Wechsler (Denver, United States of America) The Pathoimmunobiology of Asthma: The Rationale for Cytokine-Targeted Inhibition in Patients with Asthma—Mechanisms of Action and Immunotherapeutic Effects of Systemic, Biologic Agents to Manage Moderate-to-Severe Asthma Rohit Katial (Denver, United States of America) Results of Clinical Trials Focused on Cytokine-Targeted Inhibition in Adult Patients with Asthma: Dosing, Outcomes, Safety and Practical Implications—What Did the TrialsTeach Us? How Do the Results Guide Us in Biologics-Based Management? What Targets? Why? When? In Which Patient Subgroups? Sally Wenzel (Pittsburgh, United States of America) Chairperson’s Summary and Near Future Vision Statement The Near Term Future and Translational Implications of Biologic Therapy for Asthma: Meeting an Unmet Need—When? In Whom? For How Long? A State-of-the-Art Update on Etablished and Emerging Trends in Biologic-Based Management Michael Wechsler (Denver, United States of America) 1688 1689 1690 1691 1692 19:00 Interactive Q&A Session 1693 Room K Session 281 17:15 - 19:15 Industry evening symposium: Disease management of COPD, AATD and NCFBE: What can we learn from real-life data? Organised by GRIFOLS, S.A. Chairs : James D. Chalmers (Perth, United Kingdom) 17:15 Introduction James D. Chalmers (Perth, United Kingdom) 1694 6 26.08.2016
Page 1:
HELP SHAPE THE FUTURE OF RESPIRATOR
Page 4 and 5:
WELCOME FROM THE CONGRESS CHAIRS ER
Page 6 and 7:
ERS LONDON 2016 Data scanning syste
Page 8 and 9:
MAPS ERS LONDON 2016 ■ CONGRESS M
Page 10 and 11:
MAPS ERS LONDON 2016 ■ EXHIBITION
Page 12 and 13:
ERS MAPSWORLD VILLAGE ERS LONDON 20
Page 14 and 15:
INVITATION JOIN US AT THE OPENING C
Page 16 and 17:
CONGRESS RESOURCES AREA Te Congress
Page 18 and 19:
ERS-SPLF Joint Session Saturday 3 S
Page 20 and 21:
ERS-CTS Joint Session Saturday 3 Se
Page 22 and 23:
PROGRAMME AT A GLANCE
Page 24 and 25:
ERS International Congress 2016 OUT
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
WORLD VILLAGE SESSIONS
Page 44 and 45:
PROGRAMME DETAILS
Page 46 and 47:
ERS International Congress 2016 DET
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
ERS International Congress 2016 Roo
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
ERS International Congress 2016 T-0
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
ERS International Congress 2016 Pla
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
ERS International Congress 2016 ICC
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
Page 270 and 271:
Page 272 and 273:
Page 274 and 275:
Page 276 and 277:
Page 278 and 279:
Page 280 and 281:
Page 282 and 283:
Page 284 and 285:
Page 286 and 287:
Page 288 and 289:
Page 290 and 291:
Page 292 and 293:
Page 294 and 295:
Page 296 and 297:
Page 298 and 299:
Page 300 and 301:
Page 302 and 303:
Page 304 and 305:
Page 306 and 307:
Page 308 and 309:
Page 310 and 311:
Page 312 and 313:
Page 314 and 315:
Page 316 and 317:
Page 318 and 319:
Page 320 and 321:
Page 322 and 323:
Page 324 and 325:
Page 326 and 327:
Page 328 and 329:
Page 330 and 331:
Page 332 and 333:
Page 334 and 335:
Page 336 and 337:
Page 338 and 339:
ERS International Congress 2016 13:
Page 340 and 341:
Page 342 and 343: ERS International Congress 2016 DET
Page 354 and 355: ERS International Congress 2016 Pla
Page 378 and 379: ERS International Congress 2016 WOR
Page 384 and 385: ERS International Congress 2016 IND
Page 388 and 389: INDUSTRY SPONSORED SESSIONS DISCLAI
Page 408 and 409: CHAIR AND COORDINATOR INDEX Name, S
Page 410 and 411: CHAIR AND COORDINATOR INDEX S., 456
Page 412 and 413: SPEAKER INDEX 4753, 4758, 4759 GIBS
Page 414 and 415: SPEAKER INDEX ZAR H., 1734 ZAVORSKY
Page 416 and 417: AUTHOR INDEX AKHTER S., PA1020, 118
Page 418 and 419: AUTHOR INDEX ARAUJO SILVA C., PA136
Page 420 and 421: AUTHOR INDEX 4323, 4866, 4869 BARBA
Page 422 and 423: AUTHOR INDEX BILTON D., PA2633, PA4
Page 424 and 425: AUTHOR INDEX BROWN M., PA5047 BROWN
Page 426 and 427: AUTHOR INDEX PA2759 CASTIGLIA D., P
Page 428 and 429: AUTHOR INDEX ALVAREZ B., PA1034 CIM
Page 430 and 431: AUTHOR INDEX D’ORAZIO C., OA1489,
Page 432 and 433: AUTHOR INDEX DEVRAJ M., PA2689 DEWA
Page 434 and 435: AUTHOR INDEX EL ANDALOUSSI M., PA25
Page 436 and 437: AUTHOR INDEX PA2634, PA2636, 3266,
Page 438 and 439: AUTHOR INDEX GARCIA MOYANO M., PA23
Page 440 and 441: AUTHOR INDEX GORHAM J., PA2820 GORI
Page 442 and 443:
AUTHOR INDEX HANIBUCHI M., PA778 HA
Page 444 and 445:
AUTHOR INDEX HOLMES L., PA4101, PA4
Page 446 and 447:
AUTHOR INDEX JADDOE V., PA3134 JADH
Page 448 and 449:
AUTHOR INDEX KANG B., PA1160, 2485
Page 450 and 451:
AUTHOR INDEX KJELDGAARD P., PA1125,
Page 452 and 453:
AUTHOR INDEX KUNA P., OA256, PA964,
Page 454 and 455:
AUTHOR INDEX PA5096 LEPEJ D., PA129
Page 456 and 457:
AUTHOR INDEX PA1311 MACEDO C., PA25
Page 458 and 459:
AUTHOR INDEX MARTÍNEZ-MEMIJE R., P
Page 460 and 461:
AUTHOR INDEX MIKURA S., PA4847 MILA
Page 462 and 463:
AUTHOR INDEX MOYA A., PA3762 MOYA A
Page 464 and 465:
AUTHOR INDEX NIKOLETOU D., PA1368 N
Page 466 and 467:
AUTHOR INDEX PA1569 OUPADIA S., PA2
Page 468 and 469:
AUTHOR INDEX OA1802, PA2083, PA2373
Page 470 and 471:
AUTHOR INDEX PPATHANASSIOU E., PA41
Page 472 and 473:
AUTHOR INDEX PA4311, PA4325 RIBEIRO
Page 474 and 475:
AUTHOR INDEX SABOGAL PINEROS Y., PA
Page 476 and 477:
AUTHOR INDEX SCHMIDT A., PA902 SCHM
Page 478 and 479:
AUTHOR INDEX SIMIDCHIEV A., PA300 S
Page 480 and 481:
AUTHOR INDEX STANCHEVA G., PA2854,
Page 482 and 483:
AUTHOR INDEX PA4357, PA4359 TAN L.,
Page 484 and 485:
AUTHOR INDEX TRIEBNER K., 629, OA49
Page 486 and 487:
AUTHOR INDEX PA601, PA1825, 2903, 3
Page 488 and 489:
AUTHOR INDEX PA3864, 4501, 4856 WAL
Page 490 and 491:
AUTHOR INDEX YAMAMOTO A., PA569, PA
show all

CONGRESS GUIDE

Create successful ePaper yourself

Delete template?

Save as template?